Xie et al. [31] confirmed the binding between METTL3 and SOX2 mRNA, and the silencing of METTL3 reduced the enrichment of SOX2 in anti-IGF2BP2 antibodies in breast cancer. The gene discussed is METTL3; the disease is breast carcinoma.